Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dermata Therapeutics Inc (NQ: DRMA ) 3.230 +0.090 (+2.87%) Streaming Delayed Price Updated: 12:45 PM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Dermata Therapeutics Inc < Previous 1 2 Next > Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules May 17, 2024 Via ACCESSWIRE Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results May 15, 2024 Via ACCESSWIRE Dermata to Present at the Emerging Growth Conference on April 3, 2024 March 27, 2024 Via ACCESSWIRE Dermata to Present at the Emerging Growth Conference on February 7, 2024 February 01, 2024 Via ACCESSWIRE Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis January 04, 2024 Via ACCESSWIRE Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results November 09, 2023 Via ACCESSWIRE Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results August 10, 2023 Via ACCESSWIRE Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules May 24, 2023 Via ACCESSWIRE Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne December 20, 2023 Via ACCESSWIRE Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols November 16, 2023 Via ACCESSWIRE Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules November 16, 2023 Via ACCESSWIRE Dermata to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 31, 2023 Via ACCESSWIRE Dermata Therapeutics Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-to-Severe Acne June 27, 2023 Via ACCESSWIRE Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results May 11, 2023 Via ACCESSWIRE Dermata Therapeutics Inc. (NASDAQ: DRMA) Highlighted for Surprising Price Action March 21, 2023 Via Investor Brand Network Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results February 21, 2023 Via ACCESSWIRE Dermata Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET June 13, 2023 Via ACCESSWIRE Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results June 08, 2023 Via ACCESSWIRE Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules May 26, 2023 Via ACCESSWIRE Dermata Therapeutics Inc. (NASDAQ: DRMA) Near Top of Volume Charts in Friday Trading May 12, 2023 Via Investor Brand Network Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package April 20, 2023 Via ACCESSWIRE Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results November 10, 2022 Via ACCESSWIRE Dermata Therapeutics Inc. (NASDAQ: DRMA) is One of Friday Morning’s Most Active Stocks March 24, 2023 Via Investor Brand Network Dermata Therapeutics Announces Closing of $5.0 Million Public Offering March 20, 2023 Via ACCESSWIRE Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering March 16, 2023 Via ACCESSWIRE Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea December 05, 2022 Via ACCESSWIRE Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 06, 2022 Via ACCESSWIRE Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase August 24, 2022 Via ACCESSWIRE Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results August 15, 2022 Via ACCESSWIRE Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea June 13, 2022 - Topline results expected in the second half of 2022 - From Dermata Therapeutics Via AccessWire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
